Hendrik Scholl (IOB, Basel, Switzerland) talks about the unmet needs in the treatment retinal dystophies and the latest research in the area.
1. Could you tell us a little about the retinal dystrophies and their prevalence?
2. What are the major unmet needs in the treatment of retinal dystrophies?
3. How can retinal dystrophies be diagnosed earlier?
4. What have been the most important advances in gene and cell therapies for retinal dystrophies?
Support: No funding was received in the production of this video.
Disclosures: Dr. Hendrik Scholl is supported by the Swiss National Science Foundation, National Center of Competence in Research Molecular Systems Engineering “Molecular Systems Engineering”, the Wellcome Trust, and the Foundation Fighting Blindness Clinical Research Institute.
Dr. Scholl is member of the Scientific Advisory Board of: Astellas Institute for Regenerative Medicine; Gensight Biologics; Ionis Pharmaceuticals, Inc.; Gyroscope Therapeutics Ltd.; ReNeuron Group Plc/Ora Inc.; and Vision Medicines, Inc. Dr. Scholl is paid consultant of: Gerson Lehrman Group; Guidepoint.
Dr. Scholl is member of the Data Monitoring and Safety Board/Committee of ReNeuron Group Plc/Ora Inc. and member of the Steering Committee of Novo Nordisk (FOCUS trial).
Dr. Scholl is co-director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) which is constituted as a non-profit foundation and receives funding from the University of Basel, the University Hospital Basel, Novartis, and the government of Basel-Stadt.
These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. Johns Hopkins University and Bayer Pharma AG have an active research collaboration and option agreement. These arrangements have also been reviewed and approved by the University of Basel (Universitätsspital Basel, USB) in accordance with its conflict of interest policies.
Dr. Hendrik Scholl is principal investigator of grants at the USB sponsored by the following entity: Kinarus AG; Novartis Pharma AG; Ophthotech Corporation; Pharma Research & Early Development (pRED) of F. Hoffmann-La Roche Ltd; Spark Therapeutics. Grants at USB are negotiated and administered by the institution (USB) which receives them on its proper accounts. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the project(s).
Share this Video
Related Videos In Retina/Vitreous
Bart Leroy, EURETINA 2022: RNA Interference Therapy for CEP290-IRD
Prof. Bart Leroy (Ghent University, Ghent, Belgium) joined touchOPHTHALMOLOGY in an interview to speak about RNA interference therapy and its advantages in treating inherited retinal diseases caused by CEP290 mutations. ‘RNA Interference Therapy for CEP290-IRD’ was presented at EURETINA 2022, 1–4 September 2022 Could you tell us a little about inherited retinal diseases (IRD) caused […]
Usha Chakravarthy, EURETINA 2022: Persistent fluid in neovascular age-related macular degeneration
The Archway study (NCT03677934) was a phase 3, randomized, active treatment–controlled trial for the treatment of nAMD, conducted at 77 study locations in the United States. We caught up with Prof. Usha Chakravarthy (Queen’s University of Belfast, Belfast, Northern Ireland) to discuss the causes of persistent fluid in neovascular age-related macular degeneration and the impact […]
Kyoko Ohno-Matsui, EURETINA 2022: Anomalies of choroidal venous structures in high myopia
In this interview on her EURETINA presentation, Prof. Kyoko Ohno-Matsui (Tokyo Medical and Dental University, Tokyo, Japan) discussed choroidal venous structures and how they change in myopic eyes. ‘Anomalies of choroidal venous structures in high myopia’ was presented at EURETINA 2022, 1–4 September 2022 What is known about the choroidal structures in myopic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!